Company intelligence / Profile preview
Bone Biologics
Burlington, Massachusetts, United Statesbonebiologics.com ↗
- Ownership
- Public · BBLG
- Development stage
- Preclinical
01
Overview
Bone Biologics is a clinical-stage biotech company focused on bone regeneration using its proprietary NELL-1 protein technology. The lead program, Nell-1/DBX (NB1), is in a pilot clinical study for spine fusion in degenerative disc disease.
- Therapeutic areas
- OtherEndocrinologyNeurology
- Modalities
- Recombinant proteinDemineralized bone matrix (DBM)
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
The Musculoskeletal Transplant Foundation (MTF) - DBM supplier [9]Harter Secrest & Emery LLP - Legal counsel [8]Weinberg & Company, P.A. - Auditors [8]
04
Financials
- Market cap
- $1.1M
- Total revenue
- $0
- Enterprise value
- $-5M
Beyond the preview
Go deeper on Bone Biologics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bone Biologics.